CH

Novartis shares dropped 3.3% on Monday morning, according to Reuters reporting, after its cholesterol drug pelacarsen failed in a large, late-stage study by not reducing heart attack and stroke risk in patients with high Lp(a). The setback casts doubt on dedicated Lp(a)-lowering therapies and increases pressure on upcoming data for the Swiss drugmaker’s pipeline. Pelacarsen … Read more